MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma

BMC Cancer

Table 1 Patient characteristics

	Primary tumour		Liver metastases		Clinical outcome
No.	Type	Treatment	Tumour burden	Largest diameter	Response	Status	Laboratory characterisation of exosomes
1	Choroidal	I-125	10-24%	15 mm	PR	Alive 29 mo	RNA, FACS, PCR
2	Choroidal	En	25-50%	25 mm	PR	Dead 25 mo	RNA
3	Choroidal	I-125 + En	10-24%	45 mm	PR	Dead 17 mo	RNA
4	Choroidal	En	<10%	20 mm	PR	Alive 17 mo	EM
5	Choroidal	En	<10%	55 mm	PR	Dead 14 mo	EC, RNA, PCR
6	Choroidal	En	10-24%	35 mm	PR	Alive 13 mo	EC, RNA, FACS
7	Choroidal	I-125	<10%	23 mm	SD	Alive 13 mo	EC, RNA, PCR
8	Choroidal	Ru-106	25-50%	100 mm	PD	Alive 11 mo	EC, RNA, PCR, FACS
9	Choroidal	En	<10%	40 mm	PR	Alive 10 mo	EC, RNA, PCR
10	Choroidal	Ru-106 + En	<10%	30 mm	SD	Alive 7 mo	EC
11	Choroidal	En	<10%	15 mm	SD	Alive 6 mo	EC
12	Choroidal	En	10-24%	25 mm	PR	Alive 5 mo	EC

I-125 = Iodine-125 brachytherapy; Ru-106 = Ruthenium-106 brachytherapy; En = Enucleation; PR = Partial response; SD = Stable disease; PD = Progressive disease; EC = Exosome concentration (peripheral blood); RNA = RNA concentration (liver perfusate); FACS = Flow cytometry (liver perfusate); PCR = Exosomal miRNA PCR array (liver perfusate); EM = Electron microscopy (liver perfusate).

ISSN: 1471-2407